Seminars in Colon & Rectal Surgery
Volume 18, Issue 2 , Pages 96-106 , June 2007

The Utility of 18F-FDG-PET in the Diagnosis and Management of Colorectal Carcinoma

References 

  1. Yonekura Y, Benua R, Brill A, et al. Increased accumulation of 2-deoxy-2-[18F]Fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med. 1982;23:1133–1137
  2. Warburg O, Posener K. Uber den stoff-wechsel der carcinomzelle. E. N Biocehm Zeitschrift. 1924;152:309–335
  3. Smith TA. Facilitative glucose transporter expression in human cancer tissue. Br J Biomed Sci. 1999;56:285–292
  4. Schoder H, Erdi YE, Chao K, et al. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. J Nucl Med. 2004;45:559–566
  5. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238:405–422
  6. Maher MM, Kalra MK, Singh A, et al. “Hot” spots in hybrid positron emission tomography/computed tomography scanning of the abdomen: protocols, indications, interpretation, responsibilities, and reimbursements. Curr Probl Diagn Radiol. 2006;35:35–54
  7. Parker S, Tong T, Bolden S, et al. Cancer statistics, 1996. CA Cancer J Clin. 1996;46:5–27
  8. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308–314
  9. Yasuda S, Takahashi W, Takagi S, et al. Factors influencing physiological FDG uptake in the intestine. Tokai J Exp Clin Med. 1998;23:241–244
  10. Engel H, Steinert H, Buck A, et al. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med. 1996;37:441–446
  11. Hannah A, Scott AM, Akhurst T, et al. Abnormal colonic accumulation of fluorine-18-FDG in pseudomembranous colitis. J Nucl Med. 1996;37:1683–1685
  12. Gutman F, Alberini J, Wartski M, et al. Incidental colonic focal lesions detected by FDG PET/CT. AJR Am J Roentgenol. 2005;185:495–500
  13. Pandit-Taskar N, Schoder H, Gonen M, et al. Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET. AJR Am J Roentgenol. 2004;183:1143–1147
  14. Zhuang H, Hickeson M, Chacko TK, et al. Incidental detection of colon cancer by FDG positron emission tomography in patients examined for pulmonary nodules. Clin Nucl Med. 2002;27:628–632
  15. Nuclear Medicine Usage Grows, Led by PET. J Nucl Med. 2006;47:9–10
  16. Friedland S, Soetikno R, Carlisle M, et al. 18-Fluorodeoxyglucose positron emission tomography has limited sensitivity for colonic adenoma and early stage colon cancer. Gastrointest Endosc. 2005;61:395–400
  17. van Kouwen MC, Nagengast FM, Jansen JB, et al. 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol. 2005;23:3713–3717
  18. Abdel-Nabi H, Doerr R, Lamonica D, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology. 1998;206:755–760
  19. Mukai M, Sadahiro S, Yasuda S, et al. Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. Oncol Rep. 2000;7:85–87
  20. Kantorova I, Lipska L, Belohlavek O, et al. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med. 2003;44:1784–1788
  21. Furukawa H, Ikuma H, Seki A, et al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. Gut. 2006;55:1007–1011
  22. August D, Ottow R, Sugarbaker P. Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev. 1984;3:303–324
  23. Fusai G, Davidson B. Management of colorectal liver metastases. Colorectal Dis. 2003;5:2–23
  24. Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol. 1995;21:517–522
  25. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg. 1996;171:21–26
  26. Huebner R, Park K, Shepherd J, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41:1177–1189
  27. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42:1S–93S
  28. Whiteford MH, Whiteford HM, Yee LF, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum. 2000;43:759–767discussion 767-770
  29. Valk P, Abella-Columna E, Haseman M, et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999;134:503–511discussion 511-513
  30. Selzner M, Hany T, Wildbrett P, et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?. Ann Surg. 2004;240:1027–1034discussion 1035-1036
  31. Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997;38:1196–1201
  32. Beets G, Penninckx F, Schiepers C, et al. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg. 1994;81:1666–1670
  33. Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002;224:748–756
  34. Fong Y, Saldinger PF, Akhurst T, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg. 1999;178:282–287
  35. Ruers TJ, Langenhoff BS, Neeleman N, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol. 2002;20:388–395
  36. Sahani D, Kalva S, Fischman A, et al. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR Am J Roentgenol. 2005;185:239–246
  37. Moertel CG, Fleming TR, Macdonald JS, et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270:943–947
  38. Flanagan F, Dehdashti F, Ogunbiyi O, et al. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg. 1998;227:319–323
  39. Choi MY, Lee KM, Chung JK, et al. Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer. Ann Nucl Med. 2005;19:123–129
  40. Cohade C, Osman M, Leal J, et al. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med. 2003;44:1797–1803
  41. Scheele J, Stangl R, Altendorf-Hofmann A, et al. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991;110:13–29
  42. Fernandez F, Drebin J, Linehan D, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438–447discussion 447-450
  43. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058–3065
  44. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003;21:4604–4610
  45. Avril N, Sassen S, Schmalfeldt B, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005;23:7445–7453
  46. Guillem J, Moore H, Akhurst T, et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg. 2004;199:1–7
  47. Denecke T, Rau B, Hoffmann KT, et al. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging?. Eur Radiol. 2005;15:1658–1666
  48. Delbeke D, Martin W. PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med. 2004;34:209–223
  49. Moore HG, Akhurst T, Larson SM, et al. A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J Am Coll Surg. 2003;197:22–28
  50. Donckier V, Van Laethem JL, Goldman S, et al. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol. 2003;84:215–223
  51. Park KC, Schwimmer J, Shepherd JE, et al. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg. 2001;233:310–319
  52. Watson AJ, Lolohea S, Robertson GM, et al. The role of positron emission tomography in the management of recurrent colorectal cancer: a review. Dis Colon Rectum. 2007;50:102–114
  53. Meta J, Seltzer M, Schiepers C, et al. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician’s perspective. J Nucl Med. 2001;42:586–590

PII: S1043-1489(07)00010-3

doi: 10.1053/j.scrs.2007.03.003

Seminars in Colon & Rectal Surgery
Volume 18, Issue 2 , Pages 96-106 , June 2007

Article Tools

* Image Usage & Resolution